2025-05-15 - Analysis Report
Okay, here's an analysis of Eli Lilly and Co (LLY) based on the provided data. I'll present the information in English, with numerical summaries followed by brief interpretations.

## Eli Lilly and Co (LLY) Stock Analysis

**Company Overview:** Eli Lilly and Co is a global pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products.

**1. Performance vs. S&P 500 (VOO)**

*   Review Stock Ticker: LLY
*   Benchmark Stock: VOO (S&P 500)
*   LLY Cumulative Return: 0.0
*   VOO Cumulative Return: 0.0
*   **Divergence Analysis:**
    *   Max Divergence: 0.0
    *   Min Divergence: 0.0
    *   Current Divergence: 0.0
    *   Relative Divergence: 0.0

**Interpretation:** Since the cumulative returns for both LLY and VOO are 0.0, there's no divergence to analyze based on this data. The divergence values all being zero suggests that the period being analyzed starts with both at the same baseline.  Further information would be needed to evaluate the relative performance.

* **Alpha, Beta Analysis**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 0.0% | 0.0% | 0.0% | 1.0 | 67.8 |
| 2016-2018  | 0.0% | 0.0% | 0.0% | 1.0 | 95.2 |
| 2017-2019  | 0.0% | 0.0% | 0.0% | 1.0 | 110.5 |
| 2018-2020  | 0.0% | 0.0% | 0.0% | 1.0 | 144.8 |
| 2019-2021  | 0.0% | 0.0% | 0.0% | 1.0 | 240.5 |
| 2020-2022  | 0.0% | 0.0% | 0.0% | 1.0 | 322.9 |
| 2021-2023  | 0.0% | 0.0% | 0.0% | 1.0 | 519.6 |
| 2022-2024  | 0.0% | 0.0% | 0.0% | 1.0 | 692.6 |
| 2023-2025  | 0.0% | 0.0% | 0.0% | 1.0 | 643.8 |

**Analysis:**
*   **CAGR (Compound Annual Growth Rate):** 0.0% across all periods indicates no growth over these periods.
*   **MDD (Maximum Drawdown):** 0.0% suggests there were no losses during these periods.
*   **Alpha:** 0.0 across all periods means the investment did not outperform the benchmark on a risk-adjusted basis.
*   **Beta:** 1.0 indicates the stock's volatility is the same as the market.
*   **Cap(B):** The market capitalization shows a general increase from 2015-2024, peaking in 2024 and then decreasing slightly in 2025.

**2. Recent Price Action**

*   Current Price: 716.38
*   Last Market Data: {'price': 717.26, 'previousClose': 746.06, 'change': -3.86}
*   5-day Moving Average: 746.938
*   20-day Moving Average: 808.086
*   60-day Moving Average: 825.684

**Interpretation:** The stock price is below all three moving averages (5-day, 20-day, and 60-day), suggesting a short-term downtrend.  The recent price change of -3.86, from a previous close of 746.06 to a price of 717.26 indicates a significant one-day drop, confirming the recent downward pressure.

**3. Technical Indicators**

*   Market Risk Indicator (MRI): 0.0 (Normally, 0.45~0.35: Low Risk, 0.4~0.3: Medium Risk, 0.5~0.65: High Risk)
*   RSI: 34.758929290846666
*   PPO: -1.546
*   Recent (20-day) Relative Divergence Change: 0.0 (-)  (Short-term decline)
*   Expected Return (%): 0.0 (Long-term, vs. S&P 500)

**Interpretation:**

*   **MRI:** An MRI of 0.0 is unusual given the provided scale. It's difficult to interpret without understanding how this indicator is calculated.
*   **RSI:** An RSI of 34.76 suggests the stock is nearing oversold territory (typically below 30). This *could* indicate a potential buying opportunity, but it's important to consider other factors.
*   **PPO:** A PPO of -1.546 indicates that the short-term moving average is below the long-term moving average, confirming the downtrend.
*   **Recent Divergence Change:** A negative change in relative divergence over the past 20 days confirms the short-term decline.
*   **Expected Return:** An expected return of 0.0% suggests that, based on the model used, the stock is not expected to outperform the S&P 500 over the long term. The recent price drop (change': -3.86) could be a significant negative event influencing these indicators.

**4. Recent News & Significant Events**

*   2025-05-11: Eli Lilly and Co (LLY) has recently made headlines due to major business developments, regulatory changes, or market events.
*   2025-05-15: Analysts are discussing Eli Lilly and Co's (LLY) recent performance and its outlook in the context of industry trends and global economic factors.
*   2025-05-12: Eli Lilly and Co (LLY)'s stock has shown notable volatility, influenced by recent news, earnings reports, or executive actions.
*   2025-05-14: Market experts highlight both risks and opportunities for Eli Lilly and Co (LLY), advising investors to monitor recent news and company announcements.

**Interpretation:** The news snippets suggest recent activity, volatility, and potential major developments affecting LLY. It highlights the importance of staying informed about company-specific news and analyst opinions.

**5. Recent Earnings Analysis**

| Date       | EPS  | Revenue    |
|------------|------|------------|
| 2025-05-01 | 3.07 | 12.73 B$   |
| 2024-10-30 | 1.08 | 11.44 B$   |
| 2024-08-08 | 3.29 | 11.30 B$   |
| 2024-04-30 | 2.49 | 8.77 B$   |
| 2025-05-01 | 2.49 | 8.77 B$   |

**Analysis:**
*   **EPS (Earnings Per Share):** EPS has fluctuated, with highs of 3.29 and 3.07 and lows around 1.08 and 2.49. It is important to note that the 2025-05-01 entry is duplicated, which may indicate an error in the data.
*   **Revenue:** Revenue generally shows an increasing trend from $8.77B to $12.73B.

**6. Financial Information**

**Revenue and Profitability**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-03-31 | $12.73B   | 82.53%        |
| 2024-12-31 | $13.53B   | 82.24%        |
| 2024-09-30 | $11.44B   | 81.02%        |
| 2024-06-30 | $11.30B   | 80.80%        |
| 2024-03-31 | $8.77B    | 80.91%        |

**Capital and Profitability**

| Quarter    | Equity    | ROE     |
|------------|-----------|---------|
| 2025-03-31 | $15.76B   | 17.50%  |
| 2024-12-31 | $14.19B   | 31.07%  |
| 2024-09-30 | $14.24B   | 6.81%   |
| 2024-06-30 | $13.56B   | 21.88%  |
| 2024-03-31 | $12.81B   | 17.51%  |

**Analysis:**
*   **Revenue and Profitability:** Revenue has generally increased over the past year, with a dip in the most recent quarter. The profit margin remains consistently high, indicating efficient operations.
*   **Capital and Profitability:** Equity has also grown steadily. ROE (Return on Equity) fluctuates, with a high in Q4 2024 and a low in Q3 2024.

**7. Overall Summary**

Based on the provided data, LLY exhibits the following key characteristics:

*   **Recent Downtrend:** The stock is currently in a short-term downtrend, confirmed by its price being below key moving averages and a negative PPO.
*   **Potential Oversold Condition:** The RSI suggests the stock might be approaching oversold territory.
*   **Strong Fundamentals:** Revenue and profit margins are generally strong, indicating a healthy underlying business.
*   **Recent Volatility & News:** Recent news suggests potential major developments affecting the company and increased stock volatility.
*   **Mixed Earnings Picture:** While revenue has been increasing, EPS has fluctuated. The latest duplication of earnings data needs to be verified for accuracy.
* **Inconsistent Initial Data:** The initial cumulative returns of 0.0 for both LLY and VOO, alongside the zero divergence values, indicate a missing starting point or an error in the data.
* **Alpha/Beta Analysis:** Alpha is zero, Beta is 1.0 suggesting the stock performs inline with the market without outperforming on a risk-adjusted basis.
* **Market Capitalization:** Market Cap has decreased from 2024 to 2025.

**Conclusion:** LLY is currently experiencing a short-term pullback, but its strong fundamentals and high profit margins suggest the company remains healthy. The recent volatility and news suggest potential upcoming catalysts. Investors should closely monitor company-specific news, earnings reports, and analyst opinions before making any investment decisions. The potentially oversold RSI level could present a buying opportunity for long-term investors, but caution is advised given the current downtrend.

**Important Note:** This analysis is based solely on the provided data. A comprehensive investment decision should consider a broader range of factors and consult with a financial advisor.
